{"title": "Our evidence", "author": null, "url": "https://cgf.cochrane.org/our-evidence", "hostname": "cochrane.org", "description": null, "sitename": "cgf.cochrane.org", "date": "2023-01-01", "cleaned_text": "Our evidence Our Reviews | |[By Subtopic](javascript:showlist('subtopic')) [New - [Transcutaneous electrical nerve stimulation (TENS) for pain control in women with primary dysmenorrhoea](https://www.cochrane.org/CD013331/MENSTR_transcutaneous-electrical-nerve-stimulation-tens-pain-control-women-primary-dysmenorrhoea)(protocol stage) stage) [Nonsteroidal BUT EXCLUDING PATHOLOGY) (2)] [Medical Therapies (0)] [DISORDERS OF MENSTRUAL with metformin and clomiphene for endometrial protection women with breast cancer on for bleeding](https://www.cochrane.org/CD010241/MENSTR_pre-operative-endometrial-thinning-agents-before-endometrial-destruction-for-heavy-menstrual-bleeding) [Overview (2)] [Interventions commonly available during pandemics (7)] [Hormone replacement therapy (5)] replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution](https://www.cochrane.org/CD001018/MENSTR_hormone-replacement-therapy-has-no-effect-on-body-weight-and-cannot-prevent-weight-gain-at-menopause.) [PREVENTION AND TREATMENT OF MEDIUM TERM PROBLEMS (2)] [PREVENTION AND TREATMENT OF LONG TERM PROBLEMS (8)] [Decision aids for the management of menopausal symptoms](https://www.cochrane.org/CD011892/MENSTR_decision-aids-management-menopausal-symptoms)(protocol stage) [PREMENSTRUAL SYNDROME (includes cyclical mood swings and premenstrual exacerbation of (7)] [PREVENTION symptoms of premenstrual syndrome](https://www.cochrane.org/CD010503/MENSTR_oestrogen-premenstrual-syndrome) [GYNAECOLOGICAL SURGERY (excluding malignant conditions but including [MEDICAL THERAPIES thromboembolism) (2)] [EVALUATION OF DIAGNOSTIC TECHNIQUES IN THE INVESTIGATION OR ASSESSMENT OF THE SUBFERTILE COUPLE (6)] [METHOD OF TESTING (6)] [Day 5 versus day 3 embryo biopsy for preimplantation genetic testing for monogenic/single gene defects](https://www.cochrane.org/CD013233/MENSTR_day-5-versus-day-3-embryo-biopsy-genetic-testing-single-gene-disorders-embryo-implantation) [EVALUATION OF SUBFERTILITY TREATMENTS RELATING TO THE FEMALE PARTNER (129)] [OLIGO/ANOVULATION. OVULATION INDUCTION BY before in vitro fertilisation (IVF) outcomes in conception techniques (9)] [Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse](https://www.cochrane.org/CD012396/MENSTR_what-effectiveness-and-safety-luteal-support-infertile-women-trying-conceive-intrauterine) [INFERTILITY [Metformin during ovulation with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome](https://www.cochrane.org/CD009090/MENSTR_metformin-during-ovulation-induction-gonadotrophins-women-polycystic-ovary-syndrome) assisted conception fertilisation (IVF) and intracytoplasmic sperm injection (ICSI))](https://www.cochrane.org/CD001894/MENSTR_assisted-hatching-fertilised-eggs-assisted-conception-ivf-and-icsi) [Day three versus day two embryo transfer following in vitro fertilization or intracytoplasmic sperm injection](https://www.cochrane.org/CD004378/MENSTR_day-three-versus-day-two-embryo-transfer-following-vitro-fertilisation-or-intracytoplasmic-sperm) [GM-CSF (granulocyte macrophage colony-stimulating factor) media for women undergoing assisted reproduction](https://www.cochrane.org/CD013497/MENSTR_growth-factor-supplemented-culture-media-women-undergoing-assisted-reproduction) [Number of embryos for transfer following in vitro fertilisation or intra-cytoplasmic sperm injection](https://www.cochrane.org/CD003416/MENSTR_number-embryos-transfer-women-undergoing-assisted-reproductive-technology-art) [Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation](https://www.cochrane.org/CD005291/MENSTR_preimplantation-genetic-testing-abnormal-chromosome-numbers-couples-undergoing-vitro-fertilisation) [Slow versus GIFT, ZIFT) (11)] [Immune therapies women history of failed implantation undergoing IVF treatment](https://www.cochrane.org/CD009602/MENSTR_immune-therapies-for-women-with-history-of-failed-implantation-undergoing-ivf-treatment)(protocol stage) [In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction](https://www.cochrane.org/CD006606/MENSTR_vitro-maturation-subfertile-women-polycystic-ovarian-syndrome-who-are-undergoing-assisted) [Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI)](https://www.cochrane.org/CD012693/MENSTR_individualised-stimulation-dose-using-ovarian-reserve-markers-women-doing-vitro-fertilisation-plus) [Interventions for 'poor responders' hyper stimulation (COH) in in-vitro fertilisation (IVF)](https://www.cochrane.org/CD004379/MENSTR_interventions-for-poor-responders-to-controlled-ovarian-hyperstimulation-coh-in-in-vitro-fertilisation-ivf) [Metabolomics for improving pregnancy outcomes in women undergoing assisted reproductive technologies](https://www.cochrane.org/CD011872/MENSTR_metabolomics-improving-pregnancy-outcomes) [Ovarian stimulation protocols (drug regimes and modalities) (17)] [Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis](https://www.cochrane.org/CD012586/MENSTR_controlled-ovarian-stimulation-protocols-assisted-reproduction-network-meta-analysis)(protocol stage) [Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles](https://www.cochrane.org/CD002808/MENSTR_gonadotrophin-releasing-hormone-agonist-for-improving-fertility) [Gonadotropin-releasing hormone agonist HCG for oocyte triggering in antagonist-assisted reproductive technology](https://www.cochrane.org/CD008046/MENSTR_gonadotropin-releasing-hormone-agonist-versus-hcg-for-oocyte-triggering-in-antagonist-assisted-reproductive-technology-cycles) [Interventions for fertility preservation in women with cancer undergoing chemotherapy](https://www.cochrane.org/CD012891/MENSTR_interventions-fertility-preservation-women-cancer-undergoing-chemotherapy)(protocol stage) [Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques](https://www.cochrane.org/CD006109/MENSTR_pretreatments-vitro-fertilisationintra-cytoplasmic-sperm-injection-cycles) [Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted technology cycles](https://www.cochrane.org/CD005354/MENSTR_recombinant-fsh-versus-urinary-gonadotrophins-hmg-purified-fsh-highly-purified-fsh-for-ovarian-hyperstimulation-in-ivf-and-icsi-cycles) [Recombinant luteinizing hormone (rLH) and recombinant follicle cryopreservation (2)] or letrozole versus standard for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction](https://www.cochrane.org/CD010240/MENSTR_tamoxifen-or-letrozole-versus-standard-methods-for-women-with-breast-cancer-who-freeze-egg-cells-or-embryos) [Endometrial preparation (7)] [Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes](https://www.cochrane.org/CD006359/MENSTR_endometrial-preparation-egg-donor-recipients-or-frozen-embryo-transfers) [Application of seminal plasma to female genital tract prior to embryo transfer in assisted reproductive technology cycles (IVF, ICSI and frozen embryo transfer)](https://www.cochrane.org/CD011809/MENSTR_seminal-fluid-application-improve-assisted-reproduction-outcomes) reproduction](https://www.cochrane.org/CD013875/MENSTR_autologous-platelet-rich-plasma-assisted-reproduction)(protocol stage) [Interventions for improving reproductive outcomes in women with recurrent implantation failure undergoing assisted reproductive techniques](https://www.cochrane.org/CD010795/MENSTR_interventions-for-improving-reproductive-outcomes-in-women-with-recurrent-implantation-failure-undergoing-assisted-reproductive-techniques)(protocol stage) [Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle](https://www.cochrane.org/CD013827/MENSTR_progestogens-prevention-luteinising-hormone-lh-surge-women-undergoing-controlled-ovarian)(protocol stage) [Intrauterine administration of human chorionic gonadotropin (hCG) women assisted reproduction](https://www.cochrane.org/CD011537/MENSTR_effect-administering-pregnancy-hormone-womb-subfertile-women-undergoing-assisted-reproduction) [Thyroxine replacement for subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism](https://www.cochrane.org/CD011009/MENSTR_thyroxine-replacement-therapy-subfertile-women-autoimmune-thyroid-disease-or-mildly-underactive) [Granulocyte-colony stimulating factor administration for subfertile women undergoing assisted reproduction](https://www.cochrane.org/CD013226/MENSTR_use-granulocyte-colony-stimulating-factor-during-vitro-fertilisation-treatment) [EVALUATION OF SUBFERTILITY TREATMENTS pelvic organ prolapse (6)] New and Updated (in the latest issue of the CLib): Updated "}